Febrile neutropenia: Practical aspects;Febrile neutropenie: Praktische aspekte

Medizinische Klinik

Volumn 93, Issue 10, 1998, Pages 598-611

  Harten, Pontus ^a   Seyfarth, Bärbel ^a   Schmitz, Norbert ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Febrile neutropenia; Review; Therapy

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; HEMOPOIETIC GROWTH FACTOR; UREIDOPENICILLIN;

ANTIBIOTIC THERAPY; DISEASE ASSOCIATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MORTALITY; NEUTROPENIA; OUTPATIENT CARE; PATIENT SELECTION; PROPHYLAXIS; PYREXIA IDIOPATHICA; REVIEW;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0032532432     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03042675     Document Type: Review

References (131)

1. American Society of Clinical Oncology, Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957-60.
2. Anaissie EJ, Vadhan-Raj S. Is it time to redefiae the management of febrile neutropenta in cancer patients? Am J Med 1995;98:221-3.
3. Anaissie EJ, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage-colony-stimulating-factor (Escherichia coli-derived) in cancer patients with fever and neutropenia Am J Med 1996; 100:17-23.
4. Anaissie EJ, Vardvarian SE, Abi-Said D. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6.
5. Aquino VM, Buchanan GR, Tkaczewski I, et al. Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Med Pediatr Oncol 1997;28:191-5.
6. Ball LM, Siddal S, van Saene H. Teicoplanin zur ambulanten Therapie des terminal kranken Kindes, Eur J Haematol 1993;51:Suppl 54:14-7.
7. Barradell LB, Bryson HM. Cefepime. Drugs 1994;47;471-505.
8. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy exhibits comparable efficacy to combination therapy with ceftazidime and arnikacin for empirical treatment of febrile neutropenic patients. Ann Hernatol (in press).
9. Behre G, Schwartz S, Lenz K, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients, Ann Hematol 1995;71:25-31.
10. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
11. Bodey GP. Infection in cancer patiencs- a continuing association. Am J Med 1986;81:11-26.
12. Bohme A, Shah PM, Stille W, et al. Prospective randomized study to compare lmipenem 1,5 g per day vs. 3.0 g per day in infections of granulocytopenic patients. J Infect 1998;36:35-42.
13. Bow EJ, Mandell LA, Louie TJ, et al. for the National Cancer Institute of Canada - Clinical Trials Group: Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 1996;125:183-90.
14. Brown AE. Neutropenia,fever and infection. Am J Med 1984;76:421-8.
15. Büchner T, Roos N. Antifungal treatment strategy in leukemia patients. Ann Hematol 1992;65:153-61.
16. Buckley MM, Brodgen RN, Barradell LB, et al. Imipenem/cilastatin. Drugs 1992;44:408-44.
17. Caillot D, Casasnovas O, Bernard A. Improved management of invasive pulnionary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
18. Chandrasekar PH, Brown WJ. Clinical issues of blood cultures. Arch Intern Med 1994;154:841-9.
19. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing committee for the international collboration on antimicrobial treatment of febrile neutropenia in children. Pediatr Infect Dis J 1997;16:346-53.
20. Comers JR, Robichaud KJ, Pizzo PA. New pulmonary infiltrates in granulocytopenic cancer parients being treated with antibiotics. Pediatr Infect Dis 1984;3:423-8.
21. Cometta A, Cahndra T, Gaya H, et al. and the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer: Monocherapy with meropenem versus combination therapy with ceftazidim plus amikacin as empirie therapy for fever in granuloeytopenic patients with cancer. Antimícrob Agents Chemother 1996;40:1108-15.
22. Cometta A, Zinner SH, DeBock R, et al. and the International Antimicrobial Therapy Cooperative group of the EORTC. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemocher 1995;39:445-52.
23. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis 1997;24:41-51.
24. Cornely OA, Hiddemann W, Link H, et al. for the Study Group of the PEG Infections in Hematology and oncology: Interventional Antimicrobial therapy in febrile neutropenic patients (PEG Study II). In: Hiddemann W, et al., eds. Acute leukemias VII. Experimental approaches and novel therapies. Berlin-Heidelberg-New York: Springer, 1998:1045-9.
25. Cornely OA, Karthaus M, Wolf HH, et al. Neue Ansätze zur Behandlung febriler Episoden neutropenischer Krebspatienten - Empirische stationäre und ambulante Therapie febriler Neutropenien mit Ceftriaxon, Antunfect Drugs Chemother 1997;15:115-9,
26. Cruciam M, Rampazzo R. Malena M, et al. Prophylaxis with fluorquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1995;23:795-805.
27. Davey PG, Williams AH. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991;27:69-73.
28. De Pauw BE, Derenski SC, Feld R, et al., for the Intercontinental Antimicrobial Study Group: Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994;120:834-44,
29. De Pauw BE, Donnelly JP, De Witte T, et al. Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1990;5:179-82.
30. DeLalla F. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations. Drugs 1997;53:789-804.
31. Dismukes WE. Minimizing the adverse effects of amphotericin B. Hosp Ther 1989;52-65.
32. Donnelly JP, Maschmeyer G, Daenen S, et al. on behalf of the EOR TC-Gnotobiotic Project Group Selective oral antimicrobial prophylaxis for the prevention of infection in acute leucemia - ciprofloxacin versus co-trimazole plus colistin. Eur J Cancer 1992;28A:873-8.
33. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trial Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic patients, J Infect Dis 1991;163.951-8.
34. EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftnaxone veraus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
35. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients Am J Med 1989;86:668-72.
36. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8
37. Fauser AA. Prophylaxe von Katheterinfektionen. Chemother J 1996;Suppl 11;26-7.
38. Feliu J, Artal A, Gonzalez-Baron M, et al Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. Antimicrob Agents Chemother 1992;36:2816-20.
39. Freifeld AG, Pizzo P. The outpatient management of febrile neutropenia in cancer patients. Oncol Huntingt 1996;10:599-616.
40. Freifeld AG, Walsh T, Marschall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
41. Gardembas-Pain M, Desablens B, Sensebe L, et al. Home treatment offebrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1997;2:485-7.
42. Glasmacher A, Marklein G, Just-Nübling G, et al. Diagnostik invasiver Mykosen bei neutropenischen Patienten mit hämatologischen Systemerkrankungen. Dtsch Med Wochenschr 1998;123;157-60.
43. Glasmacher A, Molitor E, Risse F, et al. Pharmacokinetical aspects of antimycotic prophylaxis with itraconazole. Onkologie 1995;18:Suppl 2:199.
44. Glenn J, Cotton D, Welsey R, et al. Anorectal infections in patients with malignant diseases. Rev Infect Dis 1988;10:42-52.
45. Goodman JL, Winston DJ, Greenfield RA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
46. Graybill JR. Lipid formulations for Amphotericin B: does the emperor need new clothes? Ann Intern Med 1996;124:921-3.
47. Groll AH, Shah PM, Mentzel C, Schneider M, Jus-Nübling G, Hubner G, Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J infect 1996;33:23.
48. Günther I. Antimikrobielle Prophylaxe. In: Sauer H, Wilmanns W, Hrsg. Antiinfektiöse Therapie in der Hämatologie und Onkologie. Gräfelfing: SMV-Verlagsges., 1990:25-36.
49. Hartmann C, Tschetter K, Habermann TM. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997;336:1776-80.
50. Hiddemann W, Maschmeyer G, Runde V, et al. Prophylaxe, Diagnostik und Therapie von Infektionen bei Patienten mit malignen Erkrankungen Internist (Berlin) 1996;37:1212-24.
51. Holdsworth MT, Duncan MH. Health care outcomes case study: febrile neutropenia. Am J Health Syst Pharm 1995;52:Suppl 4:15-8.
52. Hughes WT, Armstrong D, Bodey GP, et al. (Infectious Diseases Society of America). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
53. Hughes WT, Armtrong D, Bodey GP, et al., for the Fever and Neutroperua Guideline Panel, Infectious Diseases Society of America. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
54. Hussein A, Elkordy M, Peters WP. The use of growth factors with antibiotics in the setting of neutropenic fever. Am J Med 1996;100:15-6.
55. Immunoeompromised Host Society Consensus Panel. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990;161:397-401.
56. Imrie KR, Prince HM, Couture F, et al Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transplant 1995;15:267-70.
57. Jansen J, Cromer M, Akard L, et al. Infection prevention in severely myelosuppressed patients: a comparison between ciprofioxacin and a regimen of selective modulation of the intestinal flora. Am J Med 1994;96:335-41.
58. Johnson PR, Yin JA, Tooth JA. High dose intravenous ciprofloxacin in febrile neutropenic patients. J Antimicrob Chemother 1990;26:Suppl F:101-7.
59. Kaplan AH, Weber DJ, Davis L, et al. Short courses of antibiotics in selected febrile neutropenic patients. Am J Med Sci 1991;302:353-4.
60. Karthaus M, Wolf HH, Kämpfe D, et al. Management of febrile neutropenia in 396 episodes in acute leukemia patients with once-daily administration of ceftriaxone. In: Hiddemann W, et al., eds. Acute leukemias VIl Experimental approaches and novel therapies. Berlin-Heidelberg-New York: Springer, 1998:1064-70.
61. Kern W, Behre G, Rudolf T, et al. for the German AML Cooperative Group. Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myeloid leukemia: Results of a Phase III multicenter study. Ia: Hiddemann W, et al., eds, Acute leukemias VII. Experimental approaches and novel therapies. Berlin-Heidelberg-New York: Springer, 1998:1071-81.
62. Kern W, Hay B, Kem P, et al. A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother 1994;38: 465-72.
63. Kieft H, Hoepelman AI, Rozenberg-Arska M, et al. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother 1994;38:415-21.
64. Klastersky J, Zinner SH, Calandra T, et al. and the EORTC Antimicrobial Therapy Cooperative Group. Empiric antimicrobial therapy for febrile granidocytopenic cancer patients. Lessons from four EOR TC Erials. Eur J Cancer Clin Oncol 1988;24:Suppl 1:35-45.
65. Kureishi A, Jewesson PJ, Rubinger M. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A associated nephrotoxicity. Antimicrob Agents Chemother 1991;35:2246-52.
66. Lecciones JA, Lee JW, Navarro EE. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-83.
67. Leutner C, Strunk H, Müller-Miny H, et al.Typische radiologische Befunde und Verlauf der invasiven Aspergillose des immunsupprimierten Patienten. Fortschr Röntgenstr 1997;167:24-31.
68. Lew MA, Kehoe R, Ritz J, et al. Ciprofloxacin versus trimethopnm/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995;13:239-50.
69. Lim SH, Smith MP, Machin SJ, et al. Eine prospektive randomisierte Studie zur prophylaktischen Gabe von Teicoplanin zur Prävention der frühen Hickman-Katheter assoziierten Sepsis bei Patienten mit malignen hämatologischen Systemerkrankungen unter intensiver Chemotherapie. Eur J Haematol 1993;51:Suppl 54:10-3.
70. Link H, Herrman F, Welte K, et al. Rationale Therapie mit G-CSF und GM-CSF. Med Klin 1994;89:429-41.
71. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991;40:302-8.
72. Lyman GH, Lyrnan CG, Sanderson RA, et al. Decision analysis ofhematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488-93.
73. Maher W, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121,492-501.
74. Malik IA, Khan WA, Karim M, et al. Feasibility of outpatient management of fever in cancer with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995,98:224-31.
75. Martino P, Girmenia C, Raccah R, et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992;49:49-52.
76. Maschmeyer G, Link H, Hiddemann W, et al Empirische antimikrobielle Therapie bei neutropenischen Patienten. Ergebnisse einer multizentnschen Studie der Arbeitsgruppe Infektionen in der Hämatologie der Paul-Ehrlich-Gesellschaft Med Klin 1994;89:114-23.
77. Maschmeyer G, Link H, Hiddemann W, et al. Pulmonary infiltrations in febrile patients wich neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994;73;2296-304.
78. Maschmeyer G, Vogt K, Hahn H, et al. Antimikrobielle Therapie bei Neutropenie. Dtsch Med Wochenschr 1997;122;864-9.
79. Maschmeyer G, Hiddemann W, Link H, et al. Management of infections during intensive treatment of hematologic malignancies. Ann Hematol 1997;75:9-16.
80. Maschmeyer G. Antibiotikaresistenz bei neurropenischen Patienten. Arzneim Ther 1997;15:137-9.
81. Maschmeyer G. Management of infections during intensified therapy of acute leukemias. In Hiddemann W, et al., eds. Acute Ieukemias VII. Experimental approaches and novel therapies. Berlin-Heidelberg-New York: Springer, 1998:1050-6.
82. Meropenem study group of Leuven, London and Nijinwegen: Equivalent efficacies of meropenein and ceftazidim as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995;36:185-200.
83. Mitchell PL, Morland B, Stevens MC, et al. Gianulocyte colony-stimulating factor in established febrile neucropenia: a randomized study of pediatric patients. J Clin Oncol 1997;15:1163-70.
84. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995;123:205-15.
85. Murphy S, Pinney RJ. Teicoplanin or vancomycin in the treatment of gram-positive infections? J Chn PharmTher 1995;20:5-11.
86. Pizzo P. Management offever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
87. Pizzo P. The value of protective isolation in preventing nosocomial infections in high risk patients. Am J Med 1981;70:631-7.
88. Preis S, Jürgens H, Friedland C, et al. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base. Klin Pädiat 1993;205:295-9.
89. Prentice HG, Hann IM, Herbrecht R, et al A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-8.
90. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997;336:1781-7.
91. Pye KG, Kelsey SM, Newland AC. Outpatient treatment of hickman-catheter infections. Lancet 1992;339:1237.
92. Raad H, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994;15:231-8.
93. Ramphal R, Gucalp R, Rotstein C, et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996;100:Suppl 6A;83-9.
94. Ranson MR, Oppenheim BA, Jackson A, et al. Double-blind placebo controlled trial of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J Hosp Infect 1990;9:95-102.
95. Rex JH, Benett JE, Sugar AM, et al., for the Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
96. Rodzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993;31:585-98.
97. Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidim with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
98. Rolston KV, Nguyen H, Amos G, et al. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 1992;169:283-91.
99. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
100. Ruckdeschel G. Wichtige Erreger - Epidemiologie, Resistenzlage. In: Sauer H, Wilmanns W, Hrsg. Antiinfektiöse Therapie in der Hämatologie und Onkologie. Gräfelfing: SMV-Verlagsges., 1991:6-15,
101. Ruhnke M, Beyer J. Antimykotische Prophylaxe bei neutropenischen und immunsupprimierten Patienten, Med Klin 1997;92:28-36.
102. Rybak MJ. Teicoplanin versus vancomycin: cost-effectiveness comparisons. Hosp Forum 1993;28:28-32.
103. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 1991;164:907-16.
104. Santolaya ME, Villarroel M, Avendano LF, et al. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis 1997;25:92-7.
105. Sehaison GS. Cost effectiveness of teicopianin and ceftriaxone: a once daily antibiotic regimen. Hosp Formul 1993;28:Suppl 1:20-2.
106. Schimpff SC, Growth factors, and empiric therapy with antibiotics: should they be used concurrently? Ann Intem Med 1994;121:538-9.
107. Schimpff SC, Scott DA, Wade JC. Infections in cancer patients: some controversial issues. Support Care Cancer 1994;2:94-104.
108. Sehöffski P, Wunder R, Petersen D, et al. Intralipid does not decrease the toxicity of amphotericin B. results of a randomized phase II-trial in neutropenic patients with fever of unknown origin or pneumonia. Blood 1996;88:10 Pt.1.
109. Siegmund R, Illiger HJ. Integration von G-CSF in Prophylaxe und Therapie des neutropenischen Fiebers. Med Klin 1996;91:82-8.
110. Sievers TM, Kubak BM, Wong-Beringer A. Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother 1996;38:333-47.
111. Simon C, Stille W. Antibiotikatherapie in Klinik und Praxis, 9. Aufl. Stuttgart: Schattauer, 1997.
112. Slavin MA, Osbome B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
113. Talcott JA, Finberg R, Mayer RJ. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8.
114. Talcott JA, Siegel RD, Finberg R. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
115. Talcott JA, Whalen A, Clark J, Rieker PP, et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction. J Clin Oncol 1994;12:107-14.
116. Teasley DG, Olson M, Gebhard RL, et al. Prospective randomised trial of metronidazole versus vancomycin for clostridium difficile associated diarrhoea and colitis. Lancet 1983;2:1043-6.
117. Uzun O, Anaissie EJ Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal (Review). Blood 1995;86:2063-71.
118. Van der Auwera P, Auon M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 1991;35: 451-7.
119. Verweij PE, Donnelly JP, Kullberg BJ, et al. Amphotericin B versus Amphotericin B plus 5-Flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 1994;22:81-5.
120. Wacker P, Halperin DS, Wyss M, et al. Early hospital discharge of children with fever and neutropenia: a prospective study. J Pediarr Hematol Oncol 1997;19:208-11.
121. Wade JC, Schimpff SC, Hargadon MT, et al A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamy cin plus nystatin in the prevention of infections in acute leucemia. N Engl J Med 1981;304:1057-62.
122. Wallrauch C, Elsner E, Milatovic D, et al. Antibiorikaresistenz der Enterokokken an Deutschland. Med Klin 1997;92:464-8.
123. Walsh T, Bodensteiner D, Hiemenz J, et al. for the Mycoses Study Group and the Empirical Antifungal Study Group. A randomized, double-blind trial of ambisome (liposomal amphotericin B) versus amphotericin B in the empirical tratment of persistently febrile neutropenic patients. 37th lnterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, 1997:Abstract LM-90.
124. Weite K, Reiter A, Mempel K, et al., on behalf of the Berlin-Frankfurt-Münster Study Group: A randomized phase III study of the efficacy of granulocyte colony stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996;87:3143-50.
125. Wingard JR, Merz WG, Rinaldi MG, et al Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
126. Winston DJ, Chandrasekar PH, Lazarus HM, at al, Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled double-blind, multi-center trial. Ann Intern Med 1993;118:937-42.
127. Winston DJ, Winston GH, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intem Med 1991;115:849-59.
128. Wiseman LR, Wagstaff AJ, Brodgen RN, et al. Meropenem. Drugs 1995;50:73-101.
129. Working Party Report. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrob Chemöther 1993;32:5-21.
130. Yamamura D, Gucalp R, Carlisle P, et al. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer partients. Antimicrob Agents Chemother 1997;41:1704-8.
131. Yu VL, Muder RR, Poorsattar A. Significance of isolation of aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Am J Med 1986;81:249-54.